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Background: Dofetilide, a class III antiarrhythmic, is a useful alternative to amiodarone in patients with atrial fibrillation (AF) and heart failure 
or coronary artery disease (CAD). Since inpatient monitoring is mandatory during drug initiation, it would be particularly helpful to better define 
predictors of response to dofetilide. We sought to identify clinical parameters associated with dofetilide success in a large cohort of patients with AF.
Methods: Two hundred and eighty-seven patients with AF started on dofetilide between 2001 and 2008 were included. Dofetilide was deemed 
effective if the patient remained on dofetilide at follow up and had no recurrences of AF clinically or by electrocardiogram. Dofetilide efficacy was 
analyzed in relation to following variables: dose, age, creatinine clearance, ejection fraction, left atrial size, diabetes, hypertension (HTN), a history of 
CAD, beta blocker use, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (ACE-I/ARB) use.
Results: After a follow up of 10.2+7.68 months, 54.7% of the patients were still on dofetilide and 26.8% were successfully maintained in sinus 
rhythm. A history of CAD was the only univariate predictor of dofetilide efficacy (OR 2.27; 95% C.I 1.29-4.01; p < 0.05). Age, HTN, ACE-I/ARB use and 
use of a higher dofetilide dose showed a trend on univariate analysis, (p<0.1), and were used in multivariate logistic regression analysis along with 
CAD (n=270). CAD remained the only significant factor associated with successful use of dofetilide in maintaining sinus rhythm (OR 2.18; 95% C.I 
1.18-4.02; p< 0.05). The overall efficacy of dofetilide in the subgroup of patients with CAD was 41.1%, compared to 23.5% in those without CAD (p< 
0.05).
Discussion: In this large cohort of patients with AF, the presence of coronary disease was a potent predictor of dofetilide success. This finding has 
important implications for dofetilide patient selection.
